Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 234 Squamous Cell Carcinoma of Head and Neck 168 Head and Neck Neoplasms 141 Lung Neoplasms 110 Esophageal Neoplasms 109 Nasopharyngeal Carcinoma 104 Uterine Cervical Neoplasms 101 Stomach Neoplasms 88 Esophageal Squamous Cell Carcinoma 86 Breast Neoplasms 69 Urinary Bladder Neoplasms 66 Small Cell Lung Carcinoma 58 Pancreatic Neoplasms 56 Neoplasms 55 Carcinoma, Squamous Cell 55 Cholangiocarcinoma 52 Ovarian Neoplasms 45 Neoplasm Metastasis 44 Oropharyngeal Neoplasms 43 Biliary Tract Neoplasms 41 Adenocarcinoma Of Esophagus 35 Recurrence 29 Mesothelioma, Malignant 28 Triple Negative Breast Neoplasms 25 Laryngeal Neoplasms 25 Nasopharyngeal Neoplasms 24 Lymphoma 24 Gallbladder Neoplasms 24 Sarcoma 21 Carcinoma 21

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumour × Cisplatin × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡